Survival from Diagnosis Early Mortality and Recorded Systemic Therapy Lines in a Turkish Small Cell Lung Cancer Analytic Cohort
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Objectives: We described survival from diagnosis, early mortality, and recorded systemic therapy lines and explored the association between baseline brain metastases and mortality in a Turkish small cell lung cancer (SCLC) cohort. Methods: This retrospective single-center study included 131 eligible adults. Observed diagnoses ranged from 12 August 2009 to 23 May 2023. All included patients had died by follow-up ascertainment. Additional brain-metastasis analyses and calendar-period comparisons were exploratory and post hoc. Treatment calendar details, immunotherapy exposure, and cranial radiotherapy details were unavailable. Results: Median overall survival (OS) was 10.41 months (95% confidence interval [CI], 8.74–13.04); 30- and 90-day mortality were 5.3% and 12.2%. First-line platinum–etoposide was recorded in 99 patients (75.6%). Of 22 limited-stage patients, 21 received concurrent thoracic chemoradiotherapy with curative intent; one patient could not start anticancer therapy after pneumonia and rapid clinical deterioration. Within extensive-stage disease, the unadjusted brain-metastasis hazard ratio (HR) was 1.67 (95% CI, 0.98–2.86; p = 0.061), the log-rank p value was 0.059, and the adjusted HR was 1.98 (95% CI, 1.07–3.66; p = 0.029). A 5000-replicate bootstrap gave a percentile 95% CI of 1.10–4.87 and a bias-corrected and accelerated (BCa) 95% CI of 0.84–3.79. The original full-cohort brain-metastasis p value was 0.033 and became 0.099 after Bonferroni or Holm adjustment across three baseline findings. Conclusions: The analyses suggested a possible association between baseline brain metastases and higher mortality, but the original full-cohort association did not meet the significance threshold after Holm correction. Sparse exposure and unmeasured confounding make this finding hypothesis-generating. Clinic-based referral selection may limit generalizability.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm15229083
Authors: Oğuzhan Kesen, Ali Çelik
Institution: Recep Tayyip Erdoğan University
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7236686945
